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L E T T E R  T O  T H E  E D I T O R
Serological response to mRNA SARS- CoV- 2 BNT162b2 vaccine 
in kidney transplant recipients depends on prior exposure to 
SARS- CoV- 2
To the Editor:
Grupper et al. have reported on a positive humoral response 
post full vaccination with mRNA SARS- CoV2 BNT162b2 in only 
51/136 (37.5%) kidney transplant recipients (KTRs) without prior 
exposure to the virus.1 We have conducted an IRB- approved 
(B707201215598– 2021/80) prospective small sample- size study 
comparing the humoral response to BNT162b2 in 40 consecutive in-
dividuals early exposed to the Belgian vaccination program, including 
20 KTRs with (n = 10, COVID- 19(+)) vs. without (n = 10, COVID- 19(−)) 
history of exposure to SARS- CoV- 2 and 20 controls including 10 
COVID- 19(+) vs. 10 COVID- 19(−). The quantification of S1/S2 IgGs by 
DiaSorin LIAISON® chemiluminescence immunoassay was performed 
at three time- points: first BNT162b2 injection (T1); second BNT162b2 
injection (T2, i.e., ~21 days post T1); and ~15 days after T2 (T3). The 
generalized linear mixed model tested the effects of time, group, 
and interactions. No epidemiological difference was observed be-
tween KTRs vs. controls, nor between COVID- 19(+) vs. COVID- 19(−) 
(Table 1). The median delay between PCR- proven COVID- 19 and T1 
was 129 [64; 352] days. None of the 20 KTRs received IV corticoste-
roids or rituximab within 12 months prior to vaccination.
At T1, the median concentration of S1/S2 IgGs in the 20 
COVID- 19(+) was 56 [0; 205] AU/ml. No IgG was detectable in 
COVID- 19(−)  individuals  (Table 1). At T2, a response was observed 
in 19/20 controls, with significantly higher IgG titers in COVID- 19(+) 
compared  to COVID- 19(−).  In KTRs, no humoral  response was ob-
served in COVID- 19(−) whereas all COVID- 19(+) showed detectable 
IgG levels. The magnitude of serological response was not differ-
ent between COVID- 19(+) KTRs and COVID- 19(+) controls (Table 1). 
At T3, all controls had measurable IgGs, with significantly higher 
titers  in COVID- 19(+) vs. COVID- 19(−).  In KTRs,  IgGs were detect-
able  in  only  1/10  COVID- 19(−)  (60  AU/ml),  whereas  IgG  levels  in 
COVID- 19(+) KTRs were similar to COVID- 19(+) controls (Table 1). 
An additional serological testing of the 10 COVID- 19(−) KTRs after 
50 days [39; 121] post T2 was positive in 3/10, with median IgG titers 
of 30 AU/ml [15; 46]. From a longitudinal point of view, serum S1/
S2 IgG levels in the 20 COVID- 19(+) KTR and non- KTR individuals 
increased significantly from T1 to T2, with no further increase from 
T2 to T3. The kinetics was different in the 10 COVID- 19(−) controls, 
with significant increases from T1 to T2 and from T2 to T3.
As a whole, a history of COVID- 19 impacts the kinetics and the 
magnitude of S1/S2 IgG development post BNT162b2 vaccination 
in KTRs, as recently demonstrated by Cucchiari et al.2 We have no 
information about the cellular response post BNT162b2 vaccina-
tion in our cohort. Consistently with recent publications, SARS- 
CoV- 2- naïve KTRs have a poor serological response to BNT162b2 
vaccine.1,3,4 One may not exclude that additional vaccine injections 
and/or a longer follow- up may eventually elicit a full humoral re-
sponse in KTRs. Still, given the current knowledge, KTRs with no 
history of PCR- proven COVID- 19 should be advised to maintain 
the WHO sanitary recommendations5 against SARS- CoV- 2 after 
BNT162b2- based vaccination. By contrast, one single BNT162b2 
injection might be sufficient in KTRs with detectable S1/S2 IgGs 
before vaccination.
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TA B L E  1 Characteristics of the cohort
Parameters
Controls n = 20 Kidney transplant recipients n = 20
p valueCOVID−19 (−) n = 10 COVID−19 (+) n = 10 COVID−19 (−) n = 10 COVID−19 (+) n = 10
Age, years 51.5 (10.5) 45.1 (10.4) 49.7 (13.8) 52.7 (13.8) 0.53
Female gender, n (%) 3 (30) 4 (40) 5 (50) 6 (60) 0.57
BMI, kg/m2 24.58 (3.28) 25.68 (2.95) 26.45 (3.84) 26.45 (4.67) 0.71
Time from KTx, months 121.7 (106.0) 77.8 (41.8) 0.57
Deceased donor, n (%) 8 (80) 9 (90) 0.53
CNIs, n (%) 10 (100) 10 (100) 1.00
Antimetabolite, n (%) 10 (100) 7 (70) 0.37
mTOR inhibitors, n (%) 0 (0) 1 (10) 1.00
Methylprednisolone, n (%) 4 (40) 5 (50) 1.00
Serum creatinine, mg/dl 1.08 (0.29) 1.55 (0.61) 0.13
Delay between COVID- 19 and 
vaccination, days
154.2 (107.1) 158.2 (77.0) 0.44
Evolution of anti- S1/S2 IgG titer
T1, median (min– max), AU/ml = first 
BNT162b2 injection




T2, median (min– max), AU/ml = second 
BNT162b2 injection




T3, median (min– max), AU/ml = ~15 days 
after T2




T4, median (min– max), AU/ml = ~50 days 
after T2
0 (0– 46)
Note: Data presented as mean (SD) unless otherwise stated.
Abbreviations: AZA, azathioprine; BMI, body mass index; CNIs, calcineurin inhibitors; KTx, kidney transplantation; MMF, mycophenolate mofetil; 
MPA, mycophenolate sodium; mTORs, mammalian target of rapamycin inhibitors.
aKTR COVID- 19(+) vs. KTR COVID- 19(−).
bControl COVID- 19(+) vs. control COVID- 19(−).
cKTR COVID- 19(+) vs. control COVID- 10(+).
dKTR COVID- 19(−) vs. control COVID- 19(−).
